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Abstract
The present study aimed to describe the cognitive status of a group of HIV-positive asymptomatic intravenous
drug users (IVDU) and changes which occurred over a 12-month follow-up period. Forty-two HIV positive
IVDU were selected and matched for age, sex, educational level and pattern of drug abuse with 39
seronegative IVDU controls. Baseline and follow-up evaluation included neuropsychological tests exploring
attention, language, memory, logic and visuomotor abilities, biological markers and clinical parameters.
About one-third of both seropositive and seronegative subjects showed at baseline slight cognitive deficits,
' which did not change during the follow-up period.
Introduction
Despite some previous controversial data, recent
findings seem to suggest that there is some in-
crease in the likelihood of detecting mild cogni-
tive disorders in asymptomic HIV-infected
patients.'"'" The mental deficit appears to be
restricted to small subgroups of patients and
does not have a significant impact on day to day
functioning. These studies, however, have been
performed exclusively on selected cohorts of
homosexual or bisexual subjects, who represent
only a part of the entire HIV population. There
are few studies investigating other risk-groups,
such as intravenous drug users (IVDU). IVDU
represents a special population, in terms of both
compliance difficulties and other confounding
factors (immunological, socio-cultural, affective
and neurobehavioural), which may increase their
vulnerability to the effects of the infection." As
such, a different natural history for IVDU may
be hypothesized. In particular, it is important to
understand whether IVDU present a different
pattern and progression of cognitive impairment
compared with other risk-groups.
Royal et al.^^ studied HIV-1 seropositive and
seronegative IVDU, who scored significantly
lower on neuropsychological tests compared with
norms from a cohort of homosexual men. The
authors suggest that HIV infection was not the
dominant cause of the neurological abnormali-
ties found. This study, however, was confounded
by a number of factors including previous head
trauma and loss of consciousness in both
seropositive and seronegative subjects.
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A longitudinal study'^ confirmed that chronic
intravenous drug use may be associated with
increased frequency of neuropsychological ab-
normalities, although there is no evidence of an
interaction with HIV infection to produce addi-
tional cognitive impairment. In another follow-
up study seropositive IVDU performed worse
than seronegative subjects and no decline over
time was detected.''' A study of an Edinburgh
cohort of HIV positive IVDU at different stages
of the disease showed significant cognitive im-
pairment only among symptomatic patients
(CDC group rV)."' '* Finally, in a recent study
on seropositive and seronegative detoxified sub-
jects HIV infection per se could not explain the
neuropsychological impairment observed."
Previous studies from our group have focused
on the interaction between HIV infection and
cognitive functioning. Moreover, tbe selection of
homosexual or bisexual asymptomatic subjects
was considered a reliable condition to avoid con-
founding factors.'*'" We have found only a
slight deficit for verbal memory in a selected
population of asymptomatic homosexuals or bi-
sexuals with longitudinal evaluation not showing
any change in neuropsychological impairment.
However, since 50% of the entire HIV popu-
lation in Italy are IVDU, the evaluation and
follow-up of this particular group in well-defined
experimental conditions represented a relevant
reference point for a reliable definition of these
cases in the asymptomatic phase, as well as for
distinguishing the effects of disease-related ver-
sus non-related factors on cognitive perform-
ance. Other reasons, mainly epidemiological,
sustain the rationale of this research, even if
results from previous studies are conclusive.''• '*
Particular points, however, need to be stressed.
First of all, there is a lack of studies on IVDU in
Italy. Secondly, as far as the socio-demographic
variables are concerned, the Italian IVDU popu-
lation shows quite different characteristics in
comparison to the same population in the
United States. In fact, all the subjects belong to
the white race and do not present significant
variations in cultural conditions.^" Moreover, our
patients were selected by excluding severe con-
founding factors, such as pre-existing neurologi-
cal and psychiatric diseases (in particular head
trauma), which may be possible causes of cogni-
tive impairment.^' Finally, as far as drug con-
sumption was concerned subjects were observed
in homogeneous and controlled conditions.
Subjects
From January 1992 two groups of IVDU outpa-
tients (46 HIV seronegative and 56 seropositive
in the asymptomatic stages of the disease) at the
Department of Infectious Diseases, University of
Pavia and SERT of Pavia, Italy, were observed.
In Italy SERT (Servizio Tossicodipendenze) are
the main organizations involved in the care of
drug users. General conditions and body mass
index were within the normal range. Subjects
with a history of severe head trauma, mental
retardation, learning disability, previous neuro-
logical or psychiatric disorders were excluded
firom the study.
A preliminary psychiatric interview and Zung's
Rating Scales^ '^ ^ ' for anxiety and depression
were administered before admission to the study
in order to exclude patients with psychotic or
affective (depression in particular) disorders, ac-
cording to DSM-III-R criteria. On this basis,
nine subjects (four seronegative and five seropos-
itive) were excluded from the study. Informed
consent was obtained from all subjects.
The patients recruited (42 seronegative and 51
seropositive) were reassessed at 12 months.
Three HIV negative subjects and four HIV posi-
tive patients did not present at the neuropsycho-
logical follow-up. Five subjects from the
seropositive group progressed to ARC/AIDS
stages. Therefore, after 1 year follow-up the data
of 39 seronegative (mean age 28.6 ( ± 4.9) years,
sex m/f 30/9, mean educational level 10.1
(± 3.0) years) and 42 seropositive (mean age
27.0 (± 5.3) years, sex m/f 31/11, mean educa-
tional level 10.9 (±2.8) years) patients were
available. Statistical analysis was performed on
these two groups only.
The two groups were comparable with respect
to age, sex distribution, years of education and
socio-demographic variables.
For drug consumption no statistical difference
could be detected between the two groups.
About 35% of seronegative patients and 20% of
seropositive patients were enrolled in a Metha-
done Maintenance Treatment Programme
(MMP). All subjects provided samples twice a
week for urine analysis. Urine specimens were
collected by members of staff (i.e. nurses) and
were screened at a Toxicology Laboratory for the
presence of morphine, cannabis, methadone, co-
caine and amphetamine. The mean dose of
methadone dispensed was 35 mg (range 25-
50 mg). The other subjects, not engaged in
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MMP, reported heroin use about once a week
during the last 6 months. Some of these were
randomly tested by urine analysis. The pattern of
consumption did not change during the follow-
up for these subjects.
The HIV patients who had been selected for
the study underwent a standard physical and
neurological examination and assessment of the
immunological profile every 6 months. All con-
trol subjects remained seronegative. In the
seropositive group CD4 lymphocyte count was
633 ±307 at baseline and 504 ± 27 at 1-year
follow-up.
Methods
Neuropsychological tests were administered at
baseline and after 12 months, in different equiv-
alent forms. The following tests were used:
• Digit Symbol (24). This test explores visuo-
motor and attentive functions. It is a sub-test
of WAIS and has been found to be very sensi-
tive to brain damage.
• Trail Making Test A and B (25). This measures
psychomotor speed and divided attention. It
has been used to test for early HlV-related
neuropsychological impairment (12);
• Finger Tapping Test. The Finger Tapping
Test is probably the most widely used test for
manual dexterity. Five-second trials of the
dominant hand are made with a brief rest
period between trials. The score is the average
of five trials (25);
• Digit span (forward and backward) (24). This
test evaluates short-term verbal memory and
attention;
• Logical memory (26) (immediate and delayed
recall (after 30')). This test assesses verbal
memory (short and long-term). The difference
between immediate and delayed recall is con-
sidered as a measure of forgetting;
• Corsi's test (27) which evaluates short-term
visuo-spatial memory;
• Visual reproduction (immediate and delayed
recall (after 30')) (26). This test, a subitem of
Wechsler Memory Scale, explores visuo-con-
structive memory functions. The difference
between immediate and delayed recall can be
considered as a measure of forgetting;
• Raven's Progressive Matrices 38 (subsets A, B,
Cj D) (27). This task investigates non verbal
intelligence and visuospatial abilities;
• Word Fluency (27). This test explores lan-
guage processes. It requires the subject to pro-
duce- as many words belonging to four
semantic categories (fruits, colours, animals
and towns) as possible. Two minutes are al-
lowed for each category.
The neuropsychological tests were administered
to all subjects under standard conditions, avoid-
ing stress, fadgue and other factors/events
infiuencing mental performance, such as fever.
No drug use was admitted within 24 h before
testing sessions.
Administration of all neuropsychological tests
took approximately 1 h. The overriding aim in
selecting the above instruments was to utilize
tests which were easy to complete, had relatively
short administration times, were sensitive to ac-
quired impairment and would measure cognitive
impairment associated with HIV infection. At 12
months' follow-up Zung's rating scales for anxi-
ety and depression were also administered in
order to assess changes in affective status. Analy-
sis of the data was carried out using ANOVA
and x^ tests.
Results
At baseline no significant differences were de-
tected between seronegative and asymptomatic
HIV infected patients for all cognitive measures
(Table 1). With respect to the norms for the
Italian population, corrected by age, sex and
education, 31% (n=12) of seronegative and
36% (n=15) of seropositive subjects scored
abnormally (2 SD below the mean of con-
trols) on at least two of the neuropsychological
measures.
At follow-up after 1 year the cognitive parame-
ters did not show significant changes in either
group. In particular, no decline in performance
for seropositive and seronegative patients was
detected. A slight but non-significant improve-
ment on some neuropsychological measures
could be attributable to practice effects. ANOVA
analysis of the interaction term group (HIV + /
HIV- ) by time (baseline/follow-up did not
show any significant changes for all cognitive
variables examined. The number of subjects who
at the baseline scored abnormally on at least two
of the neuropsychological measures did not
change over time in both groups (x^ test: 0.05,
NS).
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Table 1. Baseline and follow-up neuropsychohgical evaluation of IVDU patients (mean ± SD)
Digit symbol
Trail Making Test
Part A
PartB
Finger tapping
Digit span
Forward
Backward
Logical memory
Immediate rec.
Delayed rec.
Forgetting %
Corsi
Visual Reproduction
Immediate rec.
Delayed rec.
Forgetting %
Raven
Word fluency
Seronegative
1st ex.
43.9 ± 11.4
39.4 ± 12
104.1 ±35
43.7 ±8.9
5.6 ±0.9
4.1 ±0.6
9.4 ±2.5
8.1 ±2.9
13.8
5.4±1.0
U.7±2.6
10.5 ±2.0
10.2
34.5 ±4.6
19.6±4.1
patients (n 39)
Ilnd ex.
46.2 ±10.3
37.1 ± 13
95.6 ±31
44.1 ±8.7
5.4 ±0.9
4.3 ±0.8
9.9 ±2.2
9.1 ±2.5
9.1
5.6 ±0.9
n.8±2.5
10.7 ±2.0
9.3
35.2 ±4.8
20.2 ±3.9
HIV +
1st ex.
42.0 ±9.9
40.4 ± 12
112.5 ±40
42.1 ±7.6
5.9 ±1.0
4.1 ±0.7
9.1±2.1
7.9 ±2.3
13.2
5.5± 1.1
10.9 ±2.1
9.8 ±2.9
9.1
33.7 ±5.2
18.9 ±4.3
patients (n 42)
Ilnd ex.
45.1 ±10.4
37.4 ± 11
99.1 ±39
42.0 ±7.4
5.7 ± 1.1
4.0 ±0.6
9.5 ±2.4
8.2 ±2.7
13.7
5.6± 1.0
11.2 ±3.4
10.1 ±3.9
9.8
34.9 ±5.5
19.3 ±3.7
Among the HlV-infected group antiretroviral
therapy (AZT) was administered in nine cases
who presented with a persistently low
(<400X10* 1) CD4 lymphocyte count, but
without presence of clinical progression. No evi-
dent effect on cognitive parameters was observ-
able in comparison with the other cases.
Conclusions
Results here show that HIV seropositive FVDU
do not differ significantly from HIV negative
drug users on a range of cognitive tests. Com-
parisons of these two groups with Italian popu-
lation norms suggest some degree of impairment.
The neuropsychological evaluation showed the
presence of slight cognitive deficits for attention,
speed of processing of information (Trail Mak-
ing A and B) and verbal memory (Digit span and
Logic Memory). The percentage of subjects who
scored abnormally on at least two neuropsycho-
logical tests were lower than those reported by
Royal et al.^^ This may be attributable to the
more restrictive selection criteria (patients with
head trauma were excluded) utilized in the pre-
sent study.
A wide range of neuropsychological deficits
(impaired memory and psychomotor speed) is
reported to be associated with substance abuse.^ *
Moreover, the active substance abuse and the
life-style that drug abuse involves (possible loss
of consciousness due to drug consumption, in-
fective complications, poor social relationships)
may favour the presence of subclinical nervous
system disorders.
The comparison of the cognitive performance
of IVDU with other HIV risk-groups, such as
homosexuals, is difficult because of different so-
cio-demographic variables and different neu-
ropsychological methods employed. In the study
by Royal et aO^ drug abusers performed
significantly lower when compared with norms
established for a cohort of homosexuals. In pre-
vious studies,'^' " asymptomatic homosexuals
showed only slight impairment on verbal mem-
ory, while other cognitive fiinctions were pre-
served. It must be stressed, however, that
previously studied homosexual subjects generally
belong to self-selected, highly educated and mo-
tivated groups, while IVDU present different
characteristics (e.g. lower educational level, dif-
ferent sex distribution and very poor compliance
rates). Further research is needed to detect
specific neuropsychological differences among
rVDU and homosexuals, using appropriate con-
trol groups.
In accordance with previous studies,"' '•*
longitudinal evaluation showed no progression
from baseline mild cognitive abnormalities in
both seropositive and seronegative subjects, in
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the absence of significant clinical changes. Tbe
slight decline in CD4 count in "seropositive sub-
jects was not related to a worsening of cognitive
functions, Tbis is consistent with recent findings,
whicb have sbown tbat CD4 levels do not pre-
dict tbe presence or degree of neuropsychologi-
cal disturbance in tbe early stages of HIV
infection,^' Also, longitudinal studies in asymp-
tomatic homosexuals have failed to reveal a grad-
ual decline in neuropsychological performance,^"
Therefore, results from this study confirm pre-
vious studies wbicb suggest tbat the cognitive
impairment in asymptomatic IVDU may not be
directly related to HFV infection. However, at
least in small groups tbe neuropsycbological
deficit migbt be, in tbe absence of severe con-
founding factors, tbe result of tbe interaction
between variables related to substance abuse and
otber factors related or unrelated to HIV infec-
tion.
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